Abstract
The treatment goal in patients with relapsing–remitting multiple sclerosis (RR-MS) is to reduce the frequency and severity of relapses and to prevent or postpone the development of disability. Large trials have demonstrated that interferon beta-1a (IFNβ-1a), IFNβ-1b, and glatiramer acetate partially meet this purpose.1 The approved drugs are well tolerated with largely transient adverse effects. Pancreatitis is not mentioned as an adverse effect in the current Summaries of Product Characteristics for IFNβ-1a. However, acute pancreatitis has been associated with IFNα-2b treatment.2 We report a case in which a life-threatening acute pancreatitis developed 8 weeks after the initiation of treatment with IFNβ-1a for RR-MS. A healthy 53-year-old man on no concurrent medication was diagnosed with MS. He started with IFNβ-1a (Rebif) 22 μg subcutaneously three times weekly 8 weeks after diagnosis. Initially, he experienced minor injection site reactions and flu-like symptoms. However, 8 weeks later, he developed symptoms of an acute …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
